Impact of hemodialysis on efficacies of the antiplatelet agents in coronary artery disease patients complicated with end-stage renal disease

Zekang Ye,Qin Wang,Inam Ullah,Qingxia Lin,Tianyu Wu,Mingwen Yang,Yuansheng Fan,Zhou Dong,Tong Wang,Jianzhen Teng,Rui Hua,Yingdan Tang,Yule Li,Xiaoxuan Gong,Liang Yuan,Zhengxian Tao,Chunjian Li

DOI: https://doi.org/10.1007/s11239-023-02924-5

2024-02-24

Journal of Thrombosis and Thrombolysis

Abstract:It is controversial whether hemodialysis affects the efficacy of the antiplatelet agents. We aimed to investigate the impact of hemodialysis on efficacies of the antiplatelet agents in coronary artery disease (CAD) patients complicated with end-stage renal disease (ESRD). 86 CAD patients complicated with ESRD requiring hemodialysis were consecutively enrolled. After 5-day treatment with aspirin and clopidogrel or ticagrelor, the platelet aggregations induced by arachidonic acid (PL AA ) or adenosine diphosphate (PL ADP ), and the P2Y 12 reaction unit (PRU) were measured before and after hemodialysis. The propensity matching score method was adopted to generate a control group with normal renal function from 2439 CAD patients. In patients taking aspirin, the PL AA remained unchanged after hemodialysis. In patients taking clopidogrel, the PL ADP (37.26 ± 17.04 vs. 31.77 ± 16.09, p = 0.029) and corresponding clopidogrel resistance (CR) rate (23 [48.9%] vs. 14 [29.8%], p = 0.022) significantly decreased after hemodialysis, though PRU remained unchanged. Subgroup analysis indicated that PL ADP significantly decreased while using polysulfone membrane (36.8 ± 17.9 vs. 31.1 ± 14.5, p = 0.024). In patients taking ticagrelor, PL ADP , and PRU remained unchanged after hemodialysis. ESRD patients had higher incidences of aspirin resistance (AR) and CR compared to those with normal renal function (AR: 16.1% vs. 0%, p = 0.001; CR: 48.4% vs. 24.8%, p = 0.024). Hemodialysis does not have negative effect on the efficacies of aspirin, clopidogrel and ticagrelor in ESRD patients with CAD. ESRD patients have higher incidences of AR and CR compared with those with normal renal function.

cardiac & cardiovascular systems,peripheral vascular disease,hematology

What problem does this paper attempt to address?

The problem that this paper attempts to solve is whether hemodialysis will affect the efficacy of anti - platelet drugs in patients with coronary artery disease (CAD) combined with end - stage renal disease (ESRD). Specifically, the study aims to explore the impact of hemodialysis on the anti - platelet effects of aspirin, clopidogrel or ticagrelor in these patients. In addition, the study also compares the differences in anti - platelet drug responses between ESRD patients and patients with normal renal function, especially the incidences of aspirin resistance (AR) and clopidogrel resistance (CR).

### Main research questions:
1. **Does hemodialysis have an impact on the anti - platelet effects of aspirin, clopidogrel and ticagrelor?**
2. **Will different types of dialysis membrane materials (such as polysulfone membrane and polyamide membrane) affect the efficacy of anti - platelet drugs?**
3. **Differences in anti - platelet drug responses between ESRD patients and patients with normal renal function, especially in terms of the incidences of AR and CR.**

### Research background:
- Among patients with coronary artery disease (CAD), especially those with end - stage renal disease (ESRD), the risk of cardiovascular events is high.
- Previous large - scale clinical trials usually excluded hemodialysis patients, so the data on the efficacy of anti - platelet treatment in these patients are limited.
- Chronic kidney disease has been reported to be an independent predictor of stent thrombosis after coronary intervention, which may be related to the weakened effect of anti - platelet drugs.

### Research methods:
- **Research design**: Single - center, open - label study.
- **Research subjects**: 86 patients with CAD combined with ESRD who need hemodialysis.
- **Main detection indicators**: Platelet aggregation rate (PLAA, PLADP) and P2Y12 reaction units (PRU) were evaluated using light transmission aggregometry (LTA) and VerifyNow P2Y12 assay.
- **Statistical analysis**: Paired - sample t - test and McNemar test were used to compare the effects of anti - platelet drugs before and after hemodialysis.

### Research results:
- **Aspirin**: After hemodialysis, there was no significant change in PLAA.
- **Clopidogrel**: After hemodialysis, PLADP decreased significantly (37.26 ± 17.04 vs. 31.77 ± 16.09, p = 0.029), but there was no significant change in PRU. Hemodialysis using polysulfone membrane further significantly reduced PLADP (36.8 ± 17.9 vs. 31.1 ± 14.5, p = 0.024).
- **Ticagrelor**: After hemodialysis, there were no significant changes in PLADP and PRU.
- **Comparison between ESRD patients and patients with normal renal function**: The incidences of AR and CR in ESRD patients before and after hemodialysis were higher than those in patients with normal renal function.

### Conclusion:
- Hemodialysis will not have a negative impact on the anti - platelet effects of aspirin, clopidogrel and ticagrelor in ESRD patients.
- Hemodialysis using polysulfone membrane may improve the response to clopidogrel.
- ESRD patients are more likely to develop aspirin resistance and clopidogrel resistance than patients with normal renal function.

Through these research results, the paper provides an important reference for clinicians, especially when choosing anti - platelet drugs and dialysis membrane materials, which helps to optimize the treatment plan for patients with CAD combined with ESRD.